Press

Press releases
Press releases

Calmark's rights issue massively oversubscribed, provides MSEK 24.3 in total

The Board of Directors of Calmark Sweden AB (publ) (“Calmark” or “the Company”) announces today the outcome of the issue of units with preferential rights for existing shareholders, which was resolved upon by the extraordinary general meeting on 6 November 2019. The rights issue has been subscribed to an amount of approximately MSEK 34.6, which corresponds to a subscription rate of approximately 142.4 percent. This provides the Company approximately MSEK 24.3 before issuance costs which amounts to approximately 2.7 MSEK. The new issue comprises 7,366,680 B shares and 2,455,560 Series TO 2 B subscription warrants.
Read more
Press releases

Ownership change in Calmark – Creades becomes third largest owner

Creades AB (publ), a listed investment company with a net asset value of more than SEK 4 billion, have subscribed for and acquired B shares and Series TO 2 B subscription warrants in Calmark Sweden AB (publ) (“Calmark” or the “Company”) corresponding to an amount of MSEK 6.3. These transactions represent 9.44 percent of the Company's shares, which entails that Creades AB (publ) now becomes the third largest shareholder of Calmark.
Read more
Press releases

Lars Wingefors, Bengt Braun and insiders subscribe for shares in Calmark amounting in total to MSEK 9

Calmark's main owner Lars Wingefors, through the company Wingefors Invest AB, has in accordance with previous commitment and supported by unit rights, subscribed for shares amounting to MSEK 4.3 in Calmark’s preferential rights issue of MSEK 24.3. He has further subscriped for shares to an additional amount of MSEK 4.3 without support of unit rights. In addition to this, Bengt Braun together with the members of the board Stefan Blomsterberg and Anna Karin Edstedt Bonamy have subscribed for shares amounting to approximately MSEK 0.4.
Read more
Press releases

Analyst Group: Calmark Share Analysis - In the starting blocks for the global launch

Read more
Press releases

Calmark publishes information memorandum in connection with fully guaranteed rights issue

Calmark Sweden AB (publ) (“Calmark” or “the Company”) is presenting an information memorandum today, on the occasion of the rights issue of units that Calmark’s extraordinary general meeting on 6 November 2019 resolved to conduct in accordance with the Board of Directors’s proposal (“the Rights issue”). If the Rights issue is fully subscribed, the Company is initially provided approximately MSEK 24.3 before issuance costs. On full exercise of all associated subscription warrants, the Company will receive between MSEK 10.3 and MSEK 16.2 additionally, before issuance costs. The Rights issue is guaranteed through subscription commitments (68 percent, of which 50 percentage points are subscriptions with the support of unit rights and 18 percentage points are subscriptions without unit rights) and guarantee commitments (32 percent), in total corresponding to 100 percent of the initial issue amount.
Read more
News

Meet with Calmark at the international trade fair MEDICA 2019

Marianne Alksnis, International Sales Director, and Anna Söderlund, CEO of Calmark, will be present at the international medical technology trade fair MEDICA in Düsseldorf, Germany, on 18 to 21 November. Calmark will both meet with operators that have shown interest in the company and initiate discussions with prospective distributors for new markets.
Read more
Press releases

Calmark receives approval from the Swedish Ethical Review Authority to conduct clinical trial at Södersjukhuset

The Swedish Ethical Review Authority has decided to approve Calmark Sweden AB's application regarding a study on newborns. The application covers the Company’s three biomarkers and comprises three parts, which will be conducted within the next few months.
Read more
Press releases

Communiqué from the extraordinary general meeting of Calmark Sweden AB (publ)

On Wednesday, 6 November 2019, Calmark Sweden AB (publ) held an extraordinary general meeting, chaired by Mathias Karlsson. The resolutions passed are summarized below. All resolutions were passed unanimously.
Read more
Press releases

Calmark extends the time plan for CE-mark of the biomarkers LDH and Glucose - market launch as according to plan

Calmark Sweden AB (publ) announces today that the Company's products for biomarkers, LDH and glucose, will not obtain their CE conformity markings until the first quarter of 2020, the market launch of products will not be affected. The Company has focused its efforts on the first biomarker, bilirubin, whose CE-mark is on schedule, and on ramping up the production lines to facilitate market launch. As a consequence, the projects for the other biomarkers have lagged behind slightly. The update of the IVDR regulatory requirements, which will go into effect in 2022, has also had an impact, primarily on the planned clinical trials.
Read more
Press releases

Results for Calmark's initial biomarker, bilirubin, are within the expected range - project enters verification and validation phase to obtain CE mark

Calmark Sweden AB (publ) announces today that the development project for the Company's first biomarker, bilirubin, is now progressing to verification and validation. This phase, which is one of the final elements of the process, is estimated to last for approximately eight weeks. When it is completed, regulatory documentation will be compiled in order to achieve the CE Mark approval. This means that bilirubin will obtain its CE mark according to plan.
Read more
Press releases

Convocation of Extraordinary General Meeting 2019 of Calmark Sweden AB (publ)

Shareholders of Calmark Sweden AB (publ), reg.no 556696-0141 (the ”Company”), are hereby convened to an Extraordinary General Meeting on Wednesday, 6 November 2019, at 3:30 p.m., which will be held at the Company's premises, Karlstad Innovation Park, Sommargatan 101A, 656 37 Karlstad, Sweden.
Read more
Press releases

Calmark announces rights issue of 24.3 MSEK guaranteed to 100 percent and advance the date for the publication of the interim report for the third quarter

The Board of Directors of Calmark Sweden AB (publ) (“Calmark” or the “Company”) has resolved to propose a rights issue consisting of B shares and subscription warrants (units) (the “Rights issue”). The Board of Directors has therefore resolved to convene an Extraordinary General Meeting on 6 November 2019 to resolve on the Rights issue. The convocation of the Extraordinary General Meeting will be issued in a separate press release. If the Rights issue is fully subscribed, the Company is initially provided approximately MSEK 24.3 before issuance costs. On full exercise of all associated subscription warrants, the Company will receive between MSEK 10.3 and 16.2 additionally, before issuance costs. The Rights issue is guaranteed through subscription commitments of 68 per cent, of which 50 per cent are subscriptions with the support of unit rights and 18 per cent subscriptions without unit rights, as well as guarantee commitments of 32 per cent, which then in total corresponds to 100 per cent of the initial issue volume. Due to the Rights issue, the Company will advance the date for the Company's interim report for the third quarter to 13 November 2019.
Read more
News

As market launch approaches, Calmark reinforces the team with an experienced International Sales Director

Calmark Sweden AB has signed an agreement with Marianne Alksnis, who will be the company's new International Sales Director. Marianne will join the company on 15 October. She will be responsible for building the wide network of distributors that will provide the framework for Calmark's sales strategy.
Read more
Press releases

Design protection granted for Calmark's reader in Vietnam

Calmark Sweden AB has received approval for the application for industrial design right for its reader in Vietnam.
Read more
Press releases

Scientific Reports publishes a paper covering an early version of Calmark's technology

Findings from Calmark's clinical study from 2015/2016, conducted in collaboration with Södersjukhuset in Stockholm, Sweden, and Vietnam National Children’s Hospital (VNCH) in Hanoi, Vietnam, will be published in the scientific journal Scientific Reports, part of the Nature Research family. The paper is titled ”A rapid smartphone-based lactate dehydrogenase test for neonatal diagnostics at the point of care” and concludes that the point-of-care (POC) method for analysis provided reliable results within four minutes. The paper is published online on June 26.
Read more
News

Calmark has started cooperation with ShortLink regarding consultancy services in electronics

Calmark Sweden AB has started cooperation with the Karlstad-based company Shortlink AB. The cooperation regards consultancy services in electronics and development of test equipment for Calmark's reader.
Read more
Press releases

Calmark announces outcome of warrant exercise

During the period 23 May – 13 June 2019, holders of subscription warrants for Series TO 1 B in Calmark Sweden AB (publ) ("Calmark) have been entitled to subscribe for shares with warrants. A total of 2 487 202 Series TO 1 B subscription warrants were exercised, corresponding to 2 487 202 B shares and an overall exercise rate of approximately 83 percent. Calmark will thus receive approximately MSEK 13.4 in proceeds from the warrant exercises, before transaction costs of approximately MSEK 0.9. Sedermera Fondkommission has acted as financial advisor in connection with the exercise period.
Read more
News

Calmark Sweden AB signs an agreement with Scandinavian CRO regarding consulting services for clinical studies

Calmark Sweden AB has today signed an agreement with Scandinavian CRO, a Clinical Research Organization with vast experience and deep knowledge in the field of clinical studies. The agreement covers consulting services regarding the planning and execution of clinical studies on Calmark's product Neo.
Read more
Press releases

Last day of trading of Series TO 1 B subscription warrants

Today, 11 June 2019, is the last day of trading of the Series TO 1 B subscription warrants that were issued in connection with Calmark Sweden AB (publ)’s ("Calmark") spring/summer 2018 issue of units prior to listing. The exercise period for the Series TO 1 B subscription warrants ends on 13 June 2019.
Read more
Press releases

Reminder of the exercise of subscription warrants of Series TO 1 B

The exercise period for the Series TO 1 B subscription warrants that were issued in connection with Calmark Sweden AB (publ)'s ("Calmark") spring/summer 2018 issue of units prior to listing is ongoing until June 13, 2019. Last day of trading of subscription warrants of Series TO 1 B is June 11, 2019. Holders of subscription warrants for Series TO 1 B are entitled, for each warrant, to subscribe for one new B share in the company at a price of SEK 5.40 per share. On full exercise of all Series TO 1 B subscription warrants, 3 000 000 B shares will be issued and Calmark will raise approximately MSEK 16.2 before issue costs.
Read more
Press releases

Design protection granted today for Calmark's readers regarding the Indian market

Calmark Sweden AB has today received approval for the application for industrial design right for its reader in India.
Read more
Press releases

Calmark receives subscription commitments for the exercise of warrants

Today, on 27 May 2019, Calmark Sweden AB (publ) (“Calmark”) is able to announce that key persons in the Board of directors, the executive management and the main shareholders have agreed in writing to exercise their respective subscription warrants. The subscription commitments correspond to the subscription of approximately 1,581,195 shares at a price of SEK 5.40 per share, or a total amount of approximately SEK 8,538,453. This means that guaranteed undertakings corresponding to about 53 percent of the total amount that the warrants can bring now has been pre-agreed in writing. The subscription commitments have not been secured by prior transaction, bank guarantee or similar. The exercise period for the Series TO 1 B subscription warrants runs between 23 May and 13 June 2019.
Read more
Press releases

The exercise period for Series TO 1 B of Calmark’s subscription warrants begins today

Today, 23 May 2019, marks the beginning of the exercise period for the Series TO 1 B subscription warrants that were issued in connection with Calmark Sweden AB (publ)’s ("Calmark") spring/summer 2018 issue of units prior to listing. The exercise period runs until and including 13 June 2019. Holders of subscription warrants for Series TO 1 B are entitled, for each warrant, to subscribe for one new B share in the company at a price of SEK 5.40 per share. On full exercise of all Series TO 1 B subscription warrants, Calmark will raise approximately MSEK 16.2 before issuance costs.
Read more
News

Calmark second best IPO in 2018 in Quality category, Micro-business grade

Calmark Sweden AB (publ) receives an Honourable Mention from SvD Börsplus‘s service IPO-guiden. Calmark was the second best company in the Quality category and the fifth best in Share price development.
Read more
Press releases

Calmark and Triolab begins negotiations for distribution in the Nordic

Calmark Sweden AB (publ) announces today that negotiations for a Nordic market sales rights agreement regarding the Calmark NEO product are to be commenced with Triolab. A letter of intent has previously been signed by the parties.
Read more
Press releases

Analyst Group: Share analysis of Calmark – Market deployment around the corner

Calmark develops a point-of-care analysis method that can provide decision-making support in the care of newborns more quickly and easily than existing methods. Calmark‘s communicated goals have been achieved earlier than expected since the 2018 listing, and the company has therefore accelerated the timetable for a global market deployment. Based on a successful market deployment in 2020, combined with growth and the profitability allowed by the business model, Calmark is projected to increase net sales to approximately MSEK 67 by 2025, with an operating margin exceeding 25 percent. Taking these predictions into account and applying relative valuation, a present value per share is calculated to be SEK 8 in the base scenario.
Read more
Press releases

The English Edition of Calmark’s Annual Report 2018 is published

Calmark Sweden AB’s Annual Report 2018 is now published in English
Read more
News

Calmark's Chairman becomes Chief Medical Officer for IBM Nordic

Mathias Karlsson, Chairman of the Board and co-founder of Calmark, will take up appointment as Chief Medical Officer for IBM Nordic on May 1st. Mathias Karlsson will remain as Calmark Sweden AB‘s Chairman of the Board.
Read more
News

Calmark is nominated for Best IPO 2018

Calmark Sweden AB (publ) is nominated for the award Best IPO Company 2018 by IPO-Guiden, a service provided by SvD Börsplus.
Read more
News

Calmark recruits new interim CFO

Calmark Sweden AB has today signed an agreement with Inhouse AB, which will provide external CFO services by way of Sara Wili-Blomé. The agreement will come into force by April 1st and will run for at least six months.
Read more
Press releases

Calmark gets a patent, regarding methodology for LDH, approved in Vietnam

The Ministry of Science and Technology in Vietnam has today approved Calmark's patent application for "Test systems for the determination of hypoxia-induced cellular injury". The patent is part of Calmark's patent family regarding the methodology around the biomarker LDH and is valid until 2030.
Read more
Press releases

Decisions on a preliminary launch plan for Calmark's products for global markets have now been taken by the Board

The Board of Directors of Calmark Sweden AB has decided on a preliminary launch plan for the company's products. In the first phase, launches are taking place in the Nordic countries, the UK and Vietnam, and then increased in step two with more countries in Europe, as well as in Singapore, Malaysia and India.
Read more
Press releases

The first single-use items produced by Frohe delivered to Calmark Sweden AB

Calmark Sweden AB today received delivery of the first single-use items produced in a production environment. Frohe AB, with whom Calmark has previously signed an agreement, has produced the first single-use products.
Read more
Press releases

Prior to the forthcoming launch in Asia, Calmark today signed an agreement with Luctor Medical for consulting services.

Calmark Sweden AB has today signed an agreement with Luctor Medical in the Netherlands, an internationally leading consulting company specializing in finding distributors for medical technology products. The agreement applies to consulting services regarding distributor networks in Asia prior to the upcoming launch.
Read more
Press releases

First reader produced by Note delivered to Calmark Sweden AB

Calmark Sweden AB has today received delivery of the first reader manufactured in a production environment. Note AB in Norrtälje, with whom Calmark has previously signed an agreement, has produced the first reader.
Read more
Press releases

Calmark Sweden AB signs an agreement with Emergo by UL in the Netherlands to start registrations outside the EU area

Calmark Sweden AB has today signed an agreement with Emergo by UL, an internationally leading company in the regulatory field. The agreement concerns consulting services regarding the registration of Calmark's products in Asia prior to the coming launch.
Read more
News

Calmark builds the organization ahead of launch - strengthens the team with a Clinical Director

Calmark's introduction of the CE marking for the bilirubin test ahead of time plan, see press release from 20190121, means that the company is now entering a new phase with strengthening the organization prior to launch and sale. First out is the role of Clinical Director and today an agreement was signed with Emma Lif.
Read more
Press releases

The Bilirubin test is prioritized in Calmark's strategy for 2019, which means that launch can take place up to six months earlier than previously communicated

The Board of Directors of Calmark Sweden AB today decided to prioritize the CE marking for bilirubin test separately, before the other tests, in order to reach the market faster and get revenues earlier.
Read more
Press releases

Calmark Sweden AB signs agreement with Frohe AB to start production of the single-use items

Calmark Sweden AB has today signed an agreement with Frohe AB, a leading Swedish production partner for the manufacture of advanced plastic parts. The agreement concerns the production of Calmark's single-use products.
Read more
Press releases

Design protection granted today for Calmark's readers regarding the Chinese market

Calmark Sweden AB has today received approval from Chinese authorities for its application for industrial design right for its reader in China.
Read more
Press releases

Calmark Sweden AB signs agreement with Note AB to start production

Calmark Sweden AB has today signed an agreement with Note AB, a leading northern European manufacturing partner with an international platform for manufacturing electronic-based products. The agreement concerns the start-up of production for Calmark's reader.
Read more
Press releases

Calmark Sweden AB and Nublis AB terminate the agreement in advance

Nublis AB has delivered consulting services in finance to Calmark since April 2018. The agreement runs until the end of June 2019 but is now cancelled as of March 31, 2019.
Read more
Press releases

Calmark has achieved all important milestones for 2018

During the day, Calmark Sweden AB has achieved the last remaining milestones previously announced for 2018. The chemistry development for LDH and glucose is now ready to move on to the next step!
Read more
Press releases

Carlmark's reader approved in electrical safety testing - an important step forward in the CE marking

Today, Calmark Sweden achieved an important milestone towards the CE marking of its product NEO, when the reader passed the electrical safety testing and was approved in accordance with the applicable standard for laboratory equipment.
Read more
Press releases

Calmark is granted design protection for the reader in the EU and the US

The World Intellectual Property Organization (WIPO) has announced that Calmark Sweden AB has been granted registration of the design for the reader in the EU and the US.
Read more
Press releases

Calmark Sweden achieves important milestones in development project

Today, Calmark Sweden achieved an important milestone regarding the single-use items that enables large-scale production. The company is now leaving the prototype stage of development of the mechanics around the single-use products. In addition, resources for key functions have been secured for the company this week.
Read more
News

Newborns in the focus of new report from UNICEF

UNICEF today released a new report on child mortality in the world.
Read more
News

Calmark Sweden AB expands management team with vital skills

Calmark Sweden AB has today hired Björn Ekberg as part-time Senior RnD Member.
Read more
Press releases

The Swedish Patent and Registration Office grants important patent to Calmark Sweden AB

PRV, the Swedish patent and registration authority, announces that Calmark's patent application regarding the company's technology will be granted for Sweden on September 18, 2018. The patent's publication number will be 540 437.
Read more
News

Calmark Sweden AB extends project management collaboration with Stravus AB

Calmark Sweden AB has extended the agreement with Stravus AB until December 2019 with the possibility of extension
Read more
Press releases

Calmark Sweden AB submits two additional patent applications

Calmark Sweden AB announced that two additional patent applications are being filed as of today. The patents relate to the company's disposable product and test method for bilirubin levels. This further strengthens the company's patent protection for the market introduction of the company's products for point-of-care analyses developed for newborns.
Read more
Press releases

Calmark Sweden AB submits two additional patent applications

Calmark Sweden AB announces that two more patent applications are submitted as of today. The patent relates to the company's single-use item and the test method for bilirubin. This further strengthens the company's patent protection in preparation of the market introduction of the company's products for point-of-care analyses developed for newborns.
Read more
Press releases

Calmark Sweden AB is listed on the Spotlight Stock Market on July 6, 2018

Read more
Press releases

The first day of trading with Calmark Sweden AB's warrants is on July 6, 2018

Read more
Press releases

Calmark's issuance of units ahead of the planned listing on Spotlight fully subscribed

On June 11, 2018, the subscription period ended for Calmark Sweden AB's ("Calmark") issuance of units at an initial high of SEK 23 thousand before the company's planned listing on the Spotlight Stock Market. The issue of units was subscribed at SEK 23 thousand, including subscription commitment, corresponding to a subscription rate of approximately 100.4%. Calmark is hereby issued at SEK 23 thousand before issuance costs, which are estimated at approximately SEK 1.8. million. During issuance, Calmark acquired approximately 250 new shareholders. The first day of trading on Spotlight is expected to be July 6, 2018. Prior to the planned listing, Calmark subsequently appointed the stock brokerage firm Sedermera Fondkommission to act as liquidity guarantor for the company's series B shares. Liquidity guarantee will commence with the company's planned listing on Spotlight.
Read more